The use of a two-tiered testing strategy for the simultaneous detection of small EGFR mutations and EGFR amplification in lung cancer

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Lewandowska, Marzena Anna ^a,b   Czubak, Karol ^c,d   Klonowska, Katarzyna ^c,d   Jozwicki, Wojciech ^e   Kowalewski, Janusz ^e   Kozlowski, Piotr ^c,d  

^a Regional Oncology Centre Bydgoszcz   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^c INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

^d POZNAN UNIVERSITY OF TECHNOLOGY   (Poland)

^e NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SCATTER FACTOR RECEPTOR; EGFR PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; COPY NUMBER VARIATION; DNA ISOLATION; EGFR GENE; ERBB2 GENE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MET GENE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NON SMALL CELL LUNG CANCER; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; EARLY CANCER DIAGNOSIS; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; POINT MUTATION; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; POINT MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84923913733     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117983     Document Type: Article

References (33)

1. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500. PMID: 15118125
2. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566. PMID: 17625570
3. Gazdar AF (2009) Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28 Suppl 1: S24-31. doi: 10.1038/onc. 2009.198 PMID: 19680293
4. Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, et al. (2010) Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29: 2346-2356. doi: 10.1038/onc. 2009.526 PMID: 20118985
5. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792. PMID: 15728811
6. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, et al. (2005) EGFR mutations in non-smallcell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23: 857-865. PMID: 15681531
7. Pennycuick A, Simpson T, Crawley D, Lal R, Santis G, et al. (2012) Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancer. Int J Clin Pract 66: 748-752. doi: 10.1111/j. 1742-1241.2012.02961.x PMID: 22805266
8. Kawahara A, Taira T, Azuma K, Tominaga M, Hattori S, et al. (2012) A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer. Lung Cancer 78: 39-44. doi: 10.1016/j.lungcan.2012.07.002 PMID: 22858448
9. Lewandowska MA, Jozwicki W, Jochymski C, Kowalewski J (2013) Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients. Oncol Rep 30: 1045-1052. doi: 10.3892/or.2013.2579 PMID: 23817662
10. Tuononen K, Maki-Nevala S, Sarhadi VK, Wirtanen A, Ronty M, et al. (2013) Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS. Genes Chromosomes Cancer 52: 503-511. doi: 10.1002/gcc.22047 PMID: 23362162
11. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, et al. (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 8: 823-859. doi: 10.1097/JTO.0b013e318290868f PMID: 23552377
12. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, et al. (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 137: 828-860. doi: 10.5858/arpa.2012-0720-OA PMID: 23551194
13. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, et al. (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 15: 415-453. doi: 10.1016/j.jmoldx.2013.03.001 PMID: 23562183
14. Marcinkowska M, Wong KK, Kwiatkowski DJ, Kozlowski P (2010) Design and generation of MLPA probe sets for combined copy number and small-mutation analysis of human genes: EGFR as an example. ScientificWorldJournal 10: 2003-2018. doi: 10.1100/tsw.2010.195 PMID: 20953551
15. Lewandowska MA, Jozwicki W, Zurawski B (2013) KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells. Mol Diagn Ther 17: 193-203. doi: 10.1007/s40291-013-0025-8 PMID: 23606169
16. Kozlowski P, Roberts P, Dabora S, Franz D, Bissler J, et al. (2007) Identification of 54 large deletions/ duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Hum Genet 121: 389-400. PMID: 17287951
17. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, et al. (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30: e57. PMID: 12060695
18. McDermott GP, Do D, Litterst CM, Maar D, Hindson CM, et al. (2013) Multiplexed target detection using DNA-binding dye chemistry in droplet digital PCR. Anal Chem 85: 11619-11627. doi: 10.1021/ ac403061n PMID: 24180464
19. Miotke L, Lau BT, Rumma RT, Ji HP (2014) High sensitivity detection and quantitation of DNA copy number and single nucleotide variants with single color droplet digital PCR. Anal Chem 86: 2618-2624. doi: 10.1021/ac403843j PMID: 24483992
20. Dopierala J, Damato BE, Lake SL, Taktak AF, Coupland SE (2010) Genetic heterogeneity in uveal melanoma assessed by multiplex ligation-dependent probe amplification. Invest Ophthalmol Vis Sci 51: 4898-4905. doi: 10.1167/iovs.09-5004 PMID: 20484589
21. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, et al. (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807-810. PMID: 17676035
22. Liang MC, Ma J, Chen L, Kozlowski P, Qin W, et al. (2010) TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene 29: 1588-1597. doi: 10.1038/onc.2009.452 PMID: 19966866
23. Jeuken J, Cornelissen S, Boots-Sprenger S, Gijsen S, Wesseling P (2006) Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn 8: 433-443. PMID: 16931583
24. Jeuken JW, Cornelissen SJ, Vriezen M, Dekkers MM, Errami A, et al. (2007) MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 87: 1055-1065. PMID: 17700563
25. van Dijk MC, Rombout PD, Boots-Sprenger SH, Straatman H, Bernsen MR, et al. (2005) Multiplex liga-tion-dependent probe amplification for the detection of chromosomal gains and losses in formalin-fixed tissue. Diagn Mol Pathol 14: 9-16. PMID: 15714058
26. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, et al. (2005) The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307: 1434-1440. PMID: 15637236
27. Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, et al. (2009) GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 459: 1085-1090. doi: 10.1038/nature08109 PMID: 19553991
28. Hwang VJ, Maar D, Regan J, Angkustsiri K, Simon TJ, et al. (2014) Mapping the deletion endpoints in individuals with 22q11.2 Deletion Syndrome by droplet digital PCR. BMC Med Genet 15: 106. doi: 10. 1186/s12881-014-0106-5 PMID: 25312060
29. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, et al. (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346. PMID: 15741570
30. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967. doi: 10.1056/NEJMoa0904554 PMID: 19692684
31. Gahr S, Stoehr R, Geissinger E, Ficker JH, Brueckl WM, et al. (2013) EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. Br J Cancer 109: 1821-1828. doi: 10.1038/bjc.2013.511 PMID: 24002608
32. Kozlowski P, Jasinska AJ, Kwiatkowski DJ (2008) New applications and developments in the use of multiplex ligation-dependent probe amplification. Electrophoresis 29: 4627-4636. doi: 10.1002/elps. 200800126 PMID: 19053154
33. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, et al. (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150: 1107-1120. doi: 10.1016/j.cell. 2012.08.029 PMID: 22980975